Should I buy or sell Viridian Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRDN shares. View VRDN analyst ratings or view top-rated stocks .

What is Viridian Therapeutics' stock price target for 2024?

11 equities research analysts have issued 1-year price targets for Viridian Therapeutics' shares. Their VRDN share price targets range from $20.00 to $46.00. On average, they anticipate the company's stock price to reach $34.60 in the next year. This suggests a possible upside of 155.7% from the stock's current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts .

How have VRDN shares performed in 2024?

Viridian Therapeutics' stock was trading at $21.78 on January 1st, 2024. Since then, VRDN shares have decreased by 37.9% and is now trading at $13.53. View the best growth stocks for 2024 here .

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our VRDN earnings forecast .

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) announced its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.28. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative trailing twelve-month return on equity of 92.04%. Viridian Therapeutics's quarterly revenue was down 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.61) EPS.

Who are Viridian Therapeutics' major shareholders?

Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.07%), Yiheng Capital Management L.P. (1.49%), Russell Investments Group Ltd. (0.50%), Rosalind Advisors Inc. (0.48%), Ikarian Capital LLC (0.00%) and Kynam Capital Management LP (0.21%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin , Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers. View institutional ownership trends .

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VRDN

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

→ Boost your retirement with these AI payouts (From InvestorPlace) (Ad)

Free VRDN Stock Alerts

$13.53

+0.08 (+0.59%)

(As of 04:27 PM ET)

Compare

Today's Range: $13.01
▼
$13.68
50-Day Range: $12.70
▼
$19.69
52-Week Range: $10.93
▼
$28.35

Volume: 1.22 million shs
Average Volume: 922,144 shs
Market Capitalization: $863.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.60

Get Viridian Therapeutics alerts:

Viridian Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 155.7% Upside
$34.60 Price Target
Short Interest: Bearish
14.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.61) to ($3.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

713th out of 917 stocks

Medical Laboratories Industry

15th out of 19 stocks

4.4

Analyst's Opinion

Consensus Rating
Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Viridian Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Viridian Therapeutics' stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
14.59% of the outstanding shares of Viridian Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Viridian Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Viridian Therapeutics has recently decreased by 4.32%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Viridian Therapeutics does not currently pay a dividend.
Dividend Growth
Viridian Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VRDN.

2.0

News and Social Media Coverage

News Sentiment
Viridian Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Viridian Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 7 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.65% of the stock of Viridian Therapeutics is held by insiders.
Read more about Viridian Therapeutics' insider trading history.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Viridian Therapeutics are expected to decrease in the coming year, from ($3.61) to ($3.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viridian Therapeutics is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viridian Therapeutics is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viridian Therapeutics has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Viridian Therapeutics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Everybody laughed when he recommended Netflix

"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.

Click here to see how it could become the No. 1 investment of the next decade.

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

VRDN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VRDN Stock News Headlines

May 19 at 4:18 AM | americanbankingnews.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5%

May 13, 2024 | markets.businessinsider.com

Viridian Therapeutics (VRDN) Gets a Buy from Stifel Nicolaus

May 13, 2024 | americanbankingnews.com

Lifesci Capital Weighs in on Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN)

May 13, 2024 | americanbankingnews.com

Q2 2024 Earnings Forecast for Viridian Therapeutics, Inc. (NASDAQ:VRDN) Issued By HC Wainwright

May 13, 2024 | americanbankingnews.com

Brokers Set Expectations for Viridian Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VRDN)

May 13, 2024 | americanbankingnews.com

B. Riley Comments on Viridian Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VRDN)

May 13, 2024 | americanbankingnews.com

Viridian Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.80) Per Share (NASDAQ:VRDN)